Kangchen Pharmaceutical (01681) Annual Report View: A high-dividend pharmaceutical company with steady performance, rich products, and double revenue and profit
In 2023, Kangchen Pharmaceutical continued the steady growth trend of performance, achieving operating income of 2.59 billion yuan (unit, same below), up 10.7% year on year; gross profit of 1.92 billion yuan, up 9.0% year on year; gross margin of 74.2%; and net profit to mother of 785 million yuan, up 14.9% year on year.
Keep integrity, innovate, and go farway丨Understand Kangchen Pharmaceutical (1681.HK)'s 2023 performance in one picture
Recently, Kangchen Pharmaceutical (1681.HK), the market leader in proprietary Chinese medicines for nephropathy, announced the results for the year ended December 31, 2023. The following will show you the 2023 annual results of Kangson Pharmaceuticals through a chart.
CONSUN PHARMA To Go Ex-Dividend On June 11th, 2024 With 0.3 HKD Dividend Per Share
March 30th - $CONSUN PHARMA(01681.HK)$ is trading ex-dividend on June 11th, 2024. Shareholders of record on June 12th, 2024 will receive 0.3 HKD dividend per share on June 21st, 2024. The ex-divid
Consun Pharmaceutical Group Sees 15% Increase in 2023 Profit
Consun Pharmaceutical Group (HKG:1681) posted a 2023 profit attributable to shareholders of 784.5 million yuan, or 0.98 yuan per share, up from 682.9 million yuan, or 0.86 yuan per share, a year earli
Conson Pharmaceutical (01681) proposes to adopt the 2024 share option plan
Zhitong Finance App News, Kangchen Pharmaceutical (01681) issued an announcement. The company adopted the 2013 share purchase plan on December 2, 2013. According to the terms of the 2013 Share Option Plan, unless otherwise terminated or amended, the 2013 Share Option Plan will be valid for 10 years from the date of its adoption and will expire on December 1, 2023. After the 2013 share option plan expires, no share options will be offered or granted. As of the date of this announcement, there were still 504.63,900 share options granted but not yet exercised in the 2013 share option plan. In view of the 2013 share option plan
Kangchen Pharmaceutical (01681.HK): Net profit increased by 14.9% in 2023 to reach $780 million with final interest of HK$0.3 per share
On March 28, Ge Longhui | Kangchen Pharmaceutical (01681.HK) announced that in 2023, the Group achieved sales revenue of about RMB 2.59 billion, an increase of about 10.7% over the previous year; profit attributable to the company's equity shareholders was approximately RMB 780 million, an increase of about 14.9% over the previous year. Basic and diluted earnings per share were approximately RMB 0.99 and RMB 0.98 respectively. The Board proposed a final dividend of HK$0.3 per share for the year 2023. Looking at the business segment, Kangchen Pharmaceutical's sales revenue in 2023 was about RMB 2.2 billion, an increase of about 1 percent over the previous year
CONSUN PHARMA: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Kangchen Pharmaceutical (01681.HK) will hold a board meeting on March 28 to approve financial statements
Gelonghui, March 7, 丨 Kangchen Pharmaceutical (01681.HK) announced that the company will hold a board meeting on March 28, 2024 to review and approve the audited comprehensive financial statements of the company and its subsidiaries for the year ended 31 December 2023; consider paying a final dividend (if any).
CONSUN PHARMA: Notice of Board Meeting
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
Consun Pharma CEO Steps Down
Consun Pharmaceutical Group (HKG:1681) Chief Executive Officer and Vice Chairperson Li Qian resigned, effective Wednesday, due to health reasons, according to a filing released Thursday. Chairman An M
Kangchen Pharmaceutical (01681.HK): An Meng was appointed as CEO (President)
Gelonghui, January 18, 丨 Kangchen Pharmaceutical (01681.HK) issued an announcement. Li Qian has resigned as the company's executive director, vice chairman of the board, CEO (president), member of the remuneration committee and all other positions in the group due to health reasons, with effect from January 17, 2024. Chairman of the Board and Executive Director An Meng has been appointed as CEO (President) with effect from January 17, 2024. Effective January 17, 2024, and after Ms Lai's resignation, An Meng has been appointed as a member of the Remuneration Committee to replace Ms Lai.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
Pioneer Securities Pharmaceutical's 24-year Strategy: Risks have been fully released, and subsequent industry valuations are expected to rise steadily
The Zhitong Finance App learned that Pioneer Securities released a research report saying that due to more scientific collection rules, after the collection gradually covered a large stock of generic drugs/high-value consumables, the performance was clear, and new performance growth points were formed after innovative products were launched one after another, and the drugs/device-related companies in the hospital will usher in a new growth cycle after their performance stabilizes.
Guotai Junan: The pharmaceutical industry has a low market risk appetite and selects “cost-effective” stocks with steady management
Guotai Junan released a research report saying that the high base effect in COVID-related fields dissipated throughout the year, and the growth rate is expected to gradually return to its own path, but Q1, especially in January-February, was still affected by the base effect of the epidemic.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
CITIC Construction Investment: The innovative drug sector has reached the bottom of the valuation to seize multi-line opportunities and focus on systematized pharmaceutical companies entering the harvest period
CITIC Construction Investment released a research report saying that the innovative pharmaceutical industry is expected to achieve good growth in 2024, and is optimistic about the sector's performance.
Wu Han of Zhongkang Technology: The key to solving the development problems of the traditional Chinese medicine industry is to break the “island effect”
The first Traditional Chinese Medicine Ecological Conference is expected to bring new opportunities and perspectives to enterprise development and industrial upgrading.
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
Guotai Junan: The pharmaceutical sector valuation system has entered a small cycle of grasping business operations during a relatively stable period
The Zhitong Finance App learned that Guotai Junan released a research report saying that in 2019-2023, the collection, epidemic, etc. affected industries. It is anticipated that 2024, regardless of whether it has had the greatest positive or negative impact, has passed, returning to the main logic driven by healthcare demand.
No Data